|
Originally published In Press as doi:10.1074/jbc.M104128200 on August 9, 2001
J. Biol. Chem., Vol. 276, Issue 45, 41648-41655, November 9, 2001
Mutational Analysis of the Different Bulge Regions of Hepatitis C
Virus Domain II and Their Influence on Internal Ribosome Entry Site
Translational Ability*
Federico
Odreman-Macchioli,
Francisco E.
Baralle , and
Emanuele
Buratti
From the International Centre for Genetic Engineering and
Biotechnology, 34012 Trieste, Italy
Received for publication, May 8, 2001, and in revised form, July 13, 2001
 |
ABSTRACT |
The hepatitis C virus (HCV) 5'-untranslated
region and, in particular, domains II to IV are involved in the
internal ribosome entry site (IRES) structure. Recent structural
evidence has shown that the function of domain II may be to hold the
coding RNA in position until the translational machinery is correctly
assembled on the decoding site. However, a comprehensive mutational and functional study concerning the importance of the different RNA regions
that compose domain II is not yet available. Therefore, we have taken
advantage of the recently proposed secondary structure of domain II to
design a series of specific mutants. The bulge regions present in the
latest secondary structure prediction of domain II were selectively
deleted, and the effects of these mutations on IRES translation
efficiency were analyzed. Our results show that the introduction of
these mutations can variably affect the degree of HCV
translation, causing a moderate to total loss of translation ability
that correlates with the severity of changes induced in the RNA
secondary structure and degree of p25 ribosomal protein UV
cross-linking, but not with the ability of the 40S ribosomal subunit to
bind the IRES. These findings support the proposed structural
role of domain II in HCV translation.
 |
INTRODUCTION |
Translation initiation in hepatitis C virus
(HCV)1 is strongly dependent
on a highly conserved RNA structure located at the 5'-end of its genome
known as the internal ribosome entry site (IRES). The presence of this
IRES allows the 40S ribosomal subunit to position itself directly on
the starting AUG codon, allowing a cap-independent mechanism of
translation initiation (1, 2). The functional studies performed to this
date on both cellular and viral IRES elements have shown that there is
a necessity to maintain specific sequence and structural elements in
the proper conformation and position to allow correct assembly of the
translational machinery, as recently reviewed in Refs. 3 and 4. In
fact, the HCV IRES is able to fold in a complex secondary structure closely resembling that of the recently isolated GB virus B (5, 6), with four domains (I to IV) (7, 8), a helical structure (9), and a
pseudoknot (10) (see Fig. 1 for a schematic diagram). The recent
crystallographic and structural analyses have revealed that these
elements fold upon themselves to adopt a unique tertiary structure that
can bind the 40S-eukaryotic initiation factor 3 complex with high
affinity (11-16). For this reason, past analyses have highlighted the
importance of maintaining the structural integrity of domains II, III,
and IV (7-10, 17-24) and the unstructured domains (25) to retain
efficient protein translation, as recently reviewed in Ref. 26.
The majority of mutational studies performed in the past have been
focused on domain III, the largest secondary structure of the HCV IRES
(17, 19-21, 23, 27), and domain IV, which includes part of the HCV
core protein coding sequence and the initiator AUG codon in a stem-loop
configuration (7, 28-30). Several cellular factors such as eukaryotic
initiation factor 3 (14, 20, 31, 32), La autoantigen (33-35),
heterogeneous ribonucleoprotein L (36), poly-C binding protein (37,
38), and poly-pyrimidine-binding protein (39-41) have been recently reported to bind in these regions and influence translation
initiation. It should be noted that although functional
preinitiation complexes can be assembled on the HCV IRES even in the
absence of any of these factors (14, 31), variations in cellular levels
of these proteins may be the reason for the recent observations that
IRES activity in vivo is dependent on the cell cycle (42)
and cell type (43).
In contrast to domain III, considerably less is known concerning the
importance of the different regions of domain II, principally due to
the fact that several alternative RNA secondary structures have been
proposed in recent years (7, 8, 44). These changes have made it
difficult to compare past mutational studies (22) with the latest
structural model, which is based not only on structural analyses but
also on the phylogenetic comparison with recently isolated HCV-related
viruses (hog cholera virus, GB virus B, and bovine viral diarrhea
virus) (8). Therefore, we have introduced a comprehensive series
of mutations and deletions in the single-stranded regions of this
domain II structure (see Fig. 1). The mutants were then analyzed for
their ability to direct IRES translation, the degree of p25 ribosomal
protein UV cross-linking, their ability to bind the 40S ribosomal
subunits (in sucrose gradient assay and footprinting analysis), and
changes in secondary structure.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Construction of the Different 5'-UTR Mutants--
All
mutants described in this study were constructed by polymerase chain
reaction, and the primer sequences are shown in Table I. All mutants were amplified from a
template plasmid containing nucleotides 1-920 described in detail
elsewhere (20). All mutants were prepared in pBluescript II KS+
(Amersham Pharmacia Biotech) using the primers in the following
combination: 1) for mutants 53-55 and 108-110, domIIaS/reverse
and domIIaAS/universal primer; 2) for mutants 61-64 and 103,
domIIbS/reverse primer and domIIbAS/universal primer; and 3) for
mutants 71-73 and 93-96, domIIcS/reverse and domIIcAS/universal
primer. Both amplification products were mixed in the same molar
proportion and subjected to a second round of amplification using the
universal and reverse primers. To obtain the double mutants, the same
group of primers was used on single deletion mutants rather than the
original template. To prepare the different set of AUG mutants, we used
the primers described in Table I using the same strategy described
above, using the 5'-wt and the 71-73 mutant as template. All
constructs were fully sequenced before their in vitro
transcription using Beckman CEQ 2000 Dye Terminator Cycle Sequencing
according to the manufacturer's instructions.
UV Cross-linking and Secondary Structure Determination--
All
Bls KS+ plasmids described in this study were linearized by digestion
with HindIII. Transcription of 2 µg of linearized plasmid
was performed in the presence of [ -32P]UTP (Amersham
Pharmacia Biotech). The specific activities of these labeled RNA
preparations were in the range of 4 × 106 cpm/µg
RNA. The UV cross-linking technique, preparation of the ribosomal salt
wash extract from COS-1 cells, and secondary structure analysis using
RNase V1, RNase T1, and S1 nuclease have already been described in
detail in a previous work (21). Briefly, the UV cross-linking assay was
performed by adding [ -32P]UTP-labeled RNA probes
(2 × 105 cpm/incubation) in a water bath for 15 min
at 30 °C with 18 µg of the ribosomal salt wash extract (or 6 pmol
of purified 40S subunits) in a 20-µl final volume. Final binding
conditions were 20 mM Hepes, pH 7.9, 72 mM KCl,
1.5 mM MgCl2, 0.78 mM magnesium acetate, 0.52 mM DTT, 3.8% glycerol, 0.75 mM
ATP, and 1 mM GTP. In the competition experiments, cold RNA
was also added as a competitor 5 min before the addition of the labeled
RNAs (the amount used is reported in the figure legends). Samples were
then transferred into the wells of an HLA plate (Nunc; InterMed) and
irradiated with UV light on ice (0.8 J, approximately 5 min) using a UV
linker (Euroclone). Unbound RNA was then digested with 30 µg of RNase A (Sigma) and 6 units of RNase T1 (Sigma) by incubation at 37 °C for
30 min in a water bath. Samples were then analyzed by 12% SDS-polyacrylamide gel electrophoresis followed by autoradiography, drying, and exposure to Kodak X-Omat AR films for 12-24 h. Films were
then scanned on a Macintosh G3 work station using Adobe Photoshop and
printed using a Phaser 400 printer.
Transfection Analysis of the Different Mutants in COS-1
Cells--
The different mutants were then excised from the Bls KS+
plasmids by cutting with XbaI-HindIII restriction
enzymes and inserted in the pSV growth hormone bicistronic
expression system for transfection experiments in COS-1 cells as
described previously (20). Briefly, COS-1 cells at 60% confluence were
transfected with 2 µg of each plasmid using
N-[1-(2,3-dioleoyloxyl)propyl]-N,N,N-trimethylammoniummethyl sulfate (Roche Molecular Biochemicals). After 48 h, the cells were
collected, and the hGH levels were quantified by an enzyme-linked immunosorbent assay kit (Roche Molecular Biochemicals) and used to
normalize the amount of cellular lysate in the Western blot procedures.
The amount of reporter core protein produced was recognized using MAb
B12.F8 and detected on Kodak autoradiographic film by enhanced
chemiluminescence analysis (ECL; Amersham Life Science) according to
the manufacturer's instructions. The film was subsequently scanned
using an Imaging Densitometre GS-670 (Bio-Rad), and each band was
quantified using the molecular Analyst program for the Macintosh
computer. Each transfection was repeated three times. When the two core
protein isoforms (the 23-kDa processed and the 25-kDa unprocessed
forms) were present, they were quantified together.
Sucrose Density Gradients of Binary IRES-40S Complexes and
Enzymatic Footprinting Analysis--
The purification of 40S ribosomal
subunits and the assembly of binary IRES-40S ribosomal complexes were
performed essentially as described previously by Odreman-Macchioli
et al. (21). Briefly, 40S ribosomal subunits were prepared
from HeLa extracts by precipitation for 4 h at 4 °C and
centrifugation at 30,000 rpm in a Beckman 60Ti rotor and resuspended in
buffer A (20 mM Tris-HCl, pH 7.6, 2 mM DTT, and
6 mM MgCl2) with 0.25 M sucrose and
150 mM KCl to a concentration of 40 A260 units/ml. This suspension was
incubated with 1 mM puromycin (Sigma) for 10 min at 0 °C
and then incubated for 10 min at 37 °C before the addition of KCl to
0.5 M final concentration. The 40S and 60S ribosomal
subunits were then separated by centrifugation of 2-ml aliquots of this
suspension through a 10-30% sucrose gradient in buffer A with 0.5 M KCl for 17 h at 4 °C and 22,000 rpm, using a
Beckman SW28 rotor. The 40S subunits were precipitated from the pooled
gradient fractions by centrifugation for 18 h at 4 °C and
50,000 rpm in a 60Ti rotor. Pellets were resuspended in buffer B (20 mM Tris-HCl, pH 7.6, 0.2 mM EDTA, 10 mM KCl, 1 mM DTT, 1 mM
MgCl2, and 0.25 M sucrose) to a final concentration of 60 A260 units/ml. Ribosomal
complexes were assembled by incubating 2 × 105 cpm of
labeled RNAs for 10 min at 30 °C in a 100-µl reaction volume
that contained buffer E (2 mM DTT, 100 mM
potassium acetate, and 20 mM Tris, pH 7.6) with 2.5 mM magnesium acetate, 100 units of RNasin (Promega), 1 mM ATP, and 6 pmol of 40S subunits. The complexes were
resolved by centrifugation through a 10-30% sucrose gradient in
buffer E with 6 mM magnesium acetate for 16 h at
4 °C and 24,000 rpm, using a Beckman SW41 rotor. The radioactivity of gradient fractions was determined by Cerenkov counting. The enzymatic footprinting analysis was performed basically as described previously by Kolupaeva et al. (15). The IRES-40S ribosomal complexes were assembled in 20-µl reaction volumes by mixing 6 pmol
of 40S subunits with 2 × 105 cpm of labeled RNAs in
binding buffer (20 mM Tris-Cl, pH 7.5, 2.5 mM
magnesium acetate, 100 mM KCl, and 2 mM DTT).
Free or 40S-IRES RNA complexes were digested by incubation for 10 min
at 30 °C with RNase T1 (Sigma) at a final concentration of 0.02 unit/µl (in the absence or presence of the 40S ribosomal subunit).
The end-labeled primer 5'-TTCGTGCTCATGGTGCACGGT-3' (complementary to
HCV nucleotides 332-352) was annealed to RNA, and the extended cDNA products (using Moloney murine leukemia virus reverse
transcriptase according to standard protocols) were analyzed by
electrophoresis on 8% polyacrylamide-7 M urea gels and
exposed to X-Omat film (Kodak) after they were dry.
 |
RESULTS |
The recent mutation/deletion studies performed on the lower
portions of HCV 5'-UTR domain III have highlighted the existence of a
very close relationship between RNA structure and IRES translational ability. Indeed, even single-nucleotide changes in selected regions (IIId and IIIe) have been reported to completely abolish IRES activity
(17, 27). It was therefore interesting to determine whether an
analogous situation could also be found in any of the single-stranded
regions of HCV domain II. Therefore, two substitutions (A54G and U63G)
were inserted in the IIa and IIb bulges of domain II (mut50), as shown
in Fig. 1. As control, we used a second
mutant (mut297) carrying an A297G substitution in stem-loop IIIe, a
mutation that was previously described to abolish IRES activity (27). Each mutant was then analyzed for translational ability (both in
vitro and in transfection assay), for complexing with the 40S ribosomal subunit, and for binding to a p25 ribosomal protein. This p25
protein has been previously identified as a ribosomal protein by
several independent studies (21, 31, 45) (15). In particular, Pestova
et al. (31) had identified this 25-kDa protein as ribosomal
protein S9 through internal sequence analysis. However, in a recent
article (46) this identification has been queried, and it has been
suggested by immunoprecipitation analysis that the ribosomal p25
protein corresponds to another ribosomal protein of similar molecular
mass, ribosomal protein S5. The binding of this protein is of
interest because p25 is the only protein described thus far whose
degree of UV cross-linking changes following mutations in the domain II
region (22). Fig. 2A
(left panel, lanes 1-3) shows a UV cross-linking assay
using a ribosomal salt wash protein extract (RSW) with each
labeled RNA. The results show that UV cross-linking of a p25 protein
can be observed for the wild type (5'-wt) and mut50, but not for
mut297. The same result is obtained using a purified 40S subunit
preparation (40S) as shown in Fig. 2A (left
panel, lanes 4-6).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of HCV IRES.
Schematic representation of the HCV 5'-UTR secondary structure
including part of the initiation coding sequence. The
boxed regions contain the two initial mutations analyzed:
mut50 (A54G and U63G) and mut297 (A297G). The principal domains are
indicated by roman numerals I to IV, and single
subdomains are also indicated. The translation initiator AUG is
indicated by the bracket.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 2.
Analysis of domain II initial single-point
mutations. A (left panel) shows a UV
cross-linking assay using COS-1 ribosomal salt wash extract (RSW,
lanes 1-3) and a purified HeLa 40S ribosomal subunit extract
(40S, lanes 4-6) in the presence of labeled
mut50, mut297, and 5'-wt RNAs. A 25-kDa protein is observed to bind
only to mut50 (lanes 2 and 5) and 5'-wt
(lanes 1 and 4) but not to mut297 (lanes
3 and 6). The right panel shows a
competition experiment using cold 5'-wt, mut50, and mut297 RNA in the
presence of labeled 5'-wt and ribosomal salt wash (lane 1, no competitor). Each cold RNA was used at 5× molar excess. The
position of the 25-kDa ribosomal protein is indicated by an
asterisk. B shows the in vitro and
in vivo IRES activity of each mutant assayed both in a
rabbit reticulocyte lysate system (top panel) and in a
transfection assay in COS-1 cells (bottom panel). In the
first assay, only the unprocessed 35S-labeled HCV core
protein is visualized by autoradiography, whereas in the second assay,
the processed (23-kDa) and nonprocessed (25-kDa) HCV core proteins are
visualized by Western blot. The two proteins were recognized using MAb
B12.F8 and detected with enhanced chemiluminescence staining.
C shows an analysis of the binary IRES-40S ribosomal complex
formation on 5'-wt, mut50, and mut297 labeled RNAs. Assays were
performed on a 10-30% sucrose density gradient with purified 40S
ribosomal subunits. The position of the binary complexes is indicated
by an arrow. Sedimentation was from right to
left.
|
|
A competition analysis was also performed to confirm the
specificity of this interaction. Fig. 2A, right panel, shows
that in keeping with the direct binding assays only cold 5'-wt and mut50 RNAs (but not cold mut297 RNA) can compete for the binding of
this protein to the HCV IRES. Both mutants were then analyzed for their
ability to drive IRES translation. In the case of mut297, we observed a
total inhibition in the translation of the HCV core protein both
in vivo and in vitro, whereas mut50 showed a
level of translation comparable with the wild type (Fig. 2B,
top and bottom panels). It should be noted that
the HCV core protein isoforms that are produced in transfection are
slightly larger than normal (25/23 kDa as opposed to 23/21 kDa) due to
the addition of a C-terminal tag sequence, as described previously
(47). We then analyzed by sucrose density gradient the ability of the
40S ribosomal subunit to bind to these mutant RNAs. Fig. 2C
shows that mut50 binds the 40S ribosomal subunits with the same
efficiency of the wild type RNA (5'-wt). On the other hand, mut297 was
totally incapable of binding the 40S ribosomal subunits, a result that
is totally consistent with the recent crystallographic data that
identify IIId, IIIe, and IIIf as the regions that contact the 40S
platform (13).
Because these single-nucleotide mutations in domain II did not affect
the translational ability of the HCV IRES, we then prepared a new set
of mutants in which all domain II bulge regions (IIa, IIb, and IIc)
were partially or completely deleted. In addition, we prepared two
additional mutants in the upper region of domain II to test the
importance of this upper stem-loop portion. A schematic representation
all these mutants is reported in Fig.
3A. We then tested the degree
of UV cross-linking of the p25 ribosomal protein. Fig. 3B
shows that all deletions introduced in the IIa, Iib, and IIc bulges
abolished the UV cross-linking signal from the p25 ribosomal protein,
with the exception of a single-nucleotide deletion in bulge IIb
( 103) and in the two upper stem-loop mutants (mut76 and mut82). To
investigate the effect of these mutations on the efficiency of the
HCV-IRES translation, we transfected each mutant in COS-1 cells in the
pSV GH bicistronic system (20), which used the HCV core protein itself
as reporter protein. Fig. 4A shows that the translation efficiency of these mutated IRESs was variable. In particular, mutants domII a, 53-55, and 93-96
showed an almost complete lack of IRES translation. On the other hand, mutants 108-110, domII b, 61-64, domII c, and 71-73
retained an intermediate level of IRES activity (ranging between 21%
and 33%) (Fig. 4B). Finally, the mutants that showed no
decrease or little decrease in the degree of p25 cross-linking (mut76
and mut82 and mutant 103) showed translation efficiencies comparable to that of the 5'-wt (Fig. 4B). The reactivity of MAb B12.F8
with the enhanced chemiluminescence substrate and HCV core protein was
determined by preparing a standard calibration curve using a
recombinant flock house virus protein displaying the B12.F8 epitope
(FHV-C3) on its surface, as described previously (48). The results,
which are shown in Fig. 4C, were used to quantify the amount
of core protein produced in each transfection experiment.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 3.
Schematic representation of domain II
deletion mutants and ribosomal protein p25 cross-linking.
A shows a schematic representation of the wild type domain
II of HCV 5'-UTR and of the mutant structures used in this study. The
arrows indicate how each series of mutants was obtained from
the original 5'-wt sequence by selectively deleting the three bulge
regions either partially or completely. In addition, two mutants in the
apical stem-loop region of domain II (mut76 and mut82) are shown.
B shows a UV cross-linking analysis of all reported mutants
in the presence of COS-1 ribosomal salt wash extract. The
asterisk indicates the position of the p25 ribosomal
protein.
|
|

View larger version (62K):
[in this window]
[in a new window]
|
Fig. 4.
Translational ability of domain II mutants in
transient transfection analysis. A (top
panel) shows a Western blot following a transfection assay in
COS-1 cells of the different 5'-UTR mutants used in this study. The two
bands (indicated by an asterisk) represent the processed
(23-kDa) and unprocessed (25-kDa) core proteins, which were recognized
using MAb B12.F8 and visualized by enhanced chemiluminescence staining.
In the bottom panel of A, a schematic
representation of these different domain II mutants is reported for
easier reference. B shows a quantification of the amount of
core protein produced by each mutant (with respect to the wild type
sequence) obtained in three independent transfection experiments
(including S.E.s). The average value obtained from each mutant is
included inside each respective bar. C
shows a standard calibration curve to calculate MAb B12.F8 reactivity
with different amounts of HCV core protein. The standard calibration
curve was obtained by blotting increasing quantities of a flock house
virus protein (FHV-C3) displaying the B12.F8 epitope on its surface
(inset).
|
|
We then tested whether this variability in IRES activity was the result
of an incorrect assembly of the 40S-IRES binary complex. However,
sucrose density centrifugation analysis performed by mixing labeled RNA
with purified 40S subunit showed that all mutants were capable of
complexing with the ribosomal subunit (Fig.
5). The similarity of all 40S-5'-UTR
binary complex profiles in the sucrose gradient analysis suggested that
none of the mutations introduced in domain II could affect the binding
of the 40S subunit to the HCV RNA, a result that is consistent with a
recent study in which no changes in binding affinity of the 40S subunit
were measured for an IRES in which the entire domain II has been
deleted (14). However, to rule out the existence of subtler changes in
the 40S subunit positioning on the HCV IRES, we performed footprinting analysis on two representative mutants ( 71-73 and domII a) that displayed 30% IRES activity and no IRES activity, respectively. The
analysis, shown in Fig. 6A,
demonstrates that the inhibition of RNase T1 cleavages on the IIId
region (GGU 265-267) after incubation with the 40S
ribosomal subunit is identical in all three IRESs, irrespective of
their translational ability.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
Sucrose gradient analysis of 40S-IRES
ribosomal complexes of domain II mutants. Sucrose gradient
centrifugation analysis of each domain II mutant. The arrows
indicate the binary IRES-40S ribosomal complexes. Assays were performed
on a 10-30% sucrose gradient with labeled RNAs and purified 40S
ribosomal subunit. Complexes were resolved by centrifugation through a
10-30% sucrose gradient. The radioactivity of gradient fractions was
determined by Cerenkov counting. Sedimentation was from
right to left. The results from three independent
experiments were analyzed, and the average amount of labeled IRES RNA
migrating with the 40S ribosomal fraction was calculated for each
mutant. The results, including S.E.s, are shown in the bottom
graph.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 6.
Footprinting analysis of wild type and mutant
40S-IRES complexes and effects of AUG shift on translation
activity. A shows an enzymatic footprinting of the
40S-IRES complex of the 5'-wt, 71-73, and dom IIa. The cDNA
products obtained by primer extension were run on a polyacrylamide gel
to show the RNase T1 sensitivity of these RNAs either alone
(lanes 2, 5, and 8) or in the presence of the 40S
subunit (lanes 3, 6, and 8). A dideoxy sequence
using the same primer of the reverse transcription extension analysis
was run in parallel. The protected region (GGU 265-267) is
indicated on the right. B shows the translation
efficiency of four AUG mutants (wt-aug339, wt-aug345, 71-73/aug339,
and 71-73/aug345) in which the initiator AUG was mutated to AAA, and
a novel AUG codon (boxed in the schematic diagrams) was
introduced three nucleotides away either in the 5' or the 3' direction.
The amount of reporter core protein synthesized by each mutant was
determined by Western blot using MAb B12.F8.
|
|
Furthermore, the work of Rijnbrand et al. (28) had shown
that when scanning is involved in the recognition of the translation initiating AUG (at position 341), it is limited to a narrow region between nucleotides 335 and 350. Therefore, a possible shift in ribosome positioning following mutations in the domain II region could
consequently cause a more efficient selection of AUG in alternative
positions with respect to the wild type. For this purpose, the AUG in
the wild type IRES and the 71-73 mutant was shifted by 3 nucleotides
in either the downstream or upstream direction, and the original AUG
was inactivated by a AUG to AAA mutation. The 71-73 mutant was
chosen on the basis that it displayed an intermediate level of IRES
efficiency (30%) that made it ideal to detect eventual further losses
(or improvements) after the shift in AUG positioning. However, as shown
in Fig. 6B, transfection analysis of these mutant IRESs
demonstrated that in all cases, the ability to translate is completely abolished.
Finally, to find further differences that might correlate with the
translational efficiency of these mutants, the influence of these two
deletions ( 71-73 and domII a) on the domain II secondary structure
was measured. A secondary structure analysis of these two mutants was
then performed using double-stranded (RNase V1) and single-stranded
specific (RNase T1 and S1 nuclease) enzymes, as reported in Fig.
7. First of all, it should be noted that
the control cleavages in the wild type domain II are completely
consistent with the latest structural model (8). Most interestingly,
deletion of the 71-73 region results in a substantially small degree
of structural change. In particular, the only difference from the wild
type structure is represented by the appearance of a prominent T1
cleavage in correspondence to the G present in the other half of the
IIc bulge (nucleotides 93-96). Nonetheless, cleavage of the apical
bulge (nucleotides 80-86) in the 71-73 is unchanged as compared
with the wild type, and the V1 cleavages are consistent with a
conservation of the double-stranded wild type regions. On the other
hand, after deletion of the IIa bulge (domII a), the secondary
structure of domain II undergoes a drastic structural change that
eliminates most of the RNase cleavages that were obtained for the wild
type domain.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 7.
RNA secondary structure analysis of wild type
and mutant domain II regions. Enzymatic determination of the RNA
secondary structure of HCV 5'-UTR domain II for the wild type sequence
(5'-wt) and the two mutants 71-73 and domII a was performed.
In vitro transcribed RNA was enzymatically digested with S1
nuclease and T1 and V1 RNases and reverse-transcribed using a
5'-end-labeled oligonucleotide. The reverse transcription products were
then separated on a 6% polyacrylamide sequencing gel. A sequencing
reaction performed with the same primer was run in parallel to
precisely determine the cleavage sites. Squares, circles,
and triangles indicate S1 nuclease and T1 and V1 RNase
cleavage sites, respectively. Black and shaded
symbols indicate high and medium cleavage intensities. The
vertical bars indicate the proposed bulge and loop regions
of domain II. No enzyme was added to the reaction mixture in lane
N. The observed cleavage sites in the wild type sequence (5'-wt)
are reported on the proposed schematic diagram of domain II (left
panel).
|
|
 |
DISCUSSION |
Initiation of translation of hepatitis C virus RNA is a
cap-independent process, which involves an IRES element that mediates internal entry of the ribosome (26). There are several IRES strategies
used by different viruses, and in this respect, the HCV IRES has
recently been shown to employ a unique method of ribosome recruitment
(14, 31). The recently published structural map of the HCV IRES bound
to the 40S ribosome obtained using cryoelectron microscopy (13) has
substantially increased our insight into the role played in the
translation mechanism by each of the IRES domains. In particular,
domain II was found to be responsible for the induction of a
conformational change in the 40S subunit that could play an important
role in translation initiation by holding the HCV coding RNA in the
decoding site of the ribosome in position until the translational
machinery is correctly assembled (13).
It should be noted that mutational analysis has been used in the past
to determine whether specific domain II nucleotide sequences were
important for efficient IRES translation (22). However, the design of
these experiments was based on an older domain II structure, and the
results of these experiments are now difficult to interpret
because the position of the stem and bulges has changed considerably
from those initial predictions (7, 8, 44). In this study, we report the
results of a systematic mutational study concerning the importance of
the RNA regions present in the latest secondary structure proposed for
domain II.
Sucrose gradient analysis of the IRES-40S complexes formed by the
mutants under study showed that all variant sequences had comparable
ability to form valid complexes. This result was confirmed by
footprinting analysis on selected mutants. This conclusion is
consistent with a recent study that analyzed an HCV IRES mutant in
which domain II had been entirely deleted, and this deletion did not
result in any change of 40S binding affinity to the HCV IRES (14).
Nonetheless, almost all our deletions have the ability to decrease the
degree of UV cross-linking of a p25 ribosomal protein to the HCV RNA, a
possible indication that in these mutants, the 40S conformational
change has not taken place (13). This decrease in IRES efficiency is
particularly evident with the modifications in the IIa region.
Interestingly, in the model by Spahn et al. (13), this
region is mapped near the location of the coding RNA in the mRNA
binding groove. It is therefore tempting to speculate that our result
reflects this close association. However, correlation between loss of
p25 degree of UV cross-linking and translational ability is not
complete. In fact, in several mutants in which p25 UV cross-linking was
abolished, we have observed a small to moderate translation efficiency.
Secondary structure analysis of these mutants has shown that a
correlation can be established between maintenance of correct domain II
secondary structure and translational ability.
The importance of secondary structure is also evident from the fact
that single-point mutations in the different bulges (mut50 and 103)
and small changes in the single-stranded region of the apical stem-loop
(mut82) do not seem to affect translation ability. In this respect, it
should be noted that the isolation of single-point mutations that do
not appreciably affect HCV IRES activity has also been confirmed by the
isolation of an HCV IRES quasispecies that contained four mutations in
the bulge regions of domain II but whose translation efficiency was
80% that of the wild type (43). Moreover, deletions in the IIc bulge
have shown a peculiar result: the double mutant domII c retains a
significant IRES activity, whereas deletion of only the right hand part
of this bulge ( 93-96) abolishes translation efficiency. This is a
situation that is quite unlike what has been observed for other parts
of the HCV IRES such as stem-loops IIId and IIIe (17, 27). A possible explanation for these observations may reside in the fact that the role
played by domain II in HCV translation is, as suggested by Spahn
et al. (13), predominantly structural. Indeed, we have performed UV cross-linking analyses on these mutants using different protein extracts (S100, nuclear extracts, ribosomal salt wash, and
purified 40S subunit) to eventually identify cellular factors that bind
domain II, but to date, we have not found any (data not shown),
a result which, although not formal proof, adds to the existing evidence.
Interestingly, a recent genetic analysis (49) of a poliovirus/HCV
chimera has proposed that the lower region of domain II may fold in an
alternative conformation to the current model (8). The most notable
difference between these two models resides in the nucleotide 108-110
region, which is in a stem position in the model by Zhao and Wimmer
(49), whereas it is present in a single-stranded bulge conformation in
the model by Honda et al. (8). Although both models are
supported by phylogenetic and RNA prediction analysis, our nuclease S1
studies support the presence of A109 in a single-stranded status (see
Fig. 7), in keeping with the structure proposed by Honda et
al. (8). One possibility that may explain this discrepancy is that
in the poliovirus/HCV chimera, the lower domain II region may fold
differently as compared with our IRES constructs. However, it is also
possible that both structures represent alternative foldings of domain
II that may occur during the viral life cycle. In fact, changes in
tertiary conformation may have important consequences for the
recruitment of trans-acting factors to IRES domains, as recently
reviewed in Ref. 4.
In conclusion, our findings support the recent model of HCV IRES-40S
ribosomal subunit interaction (13) and the structural role played
therein by domain II. In addition, our results identify the IIa bulge
region as the most efficient target for antisense inhibition of HCV
translation, a promising approach in the search for HCV-specific
inhibitors (17, 50).
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: International Centre
for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy. Tel.: 39-40-3757337; Fax: 39-40-3757361; E-mail:
baralle@icgeb.trieste.it.
Published, JBC Papers in Press, August 9, 2001, DOI 10.1074/jbc.M104128200
 |
ABBREVIATIONS |
The abbreviations used are:
HCV, hepatitis C
virus;
IRES, internal ribosome entry site;
DTT, dithiothreitol;
MAb, monoclonal antibody;
UTR, untranslated region;
wt, wild type.
 |
REFERENCES |
| 1.
|
Merrick, W. C.,
and Hershey, J. W. B.
(1996)
in
Translational Control
(Hershey, J. W. B.
, Mathews, M. B.
, and Sonenberg, N., eds)
, pp. 31-69, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 2.
|
Jackson, R. J.,
Howell, M. T.,
and Kaminski, A.
(1990)
Trends Biochem. Sci.
15,
477-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Jackson, R. J.
(2000)
in
Translational Control of Gene Expression
(Hershey, J. W. B.
, Mathews, M. B.
, and Sonenberg, N., eds)
, pp. 127-184, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 4.
|
Martinez-Salas, E.,
Ramos, R.,
Lafuente, E.,
and Lopez De Quinto, S.
(2001)
J. Gen. Virol.
82,
973-984[Free Full Text]
|
| 5.
|
Grace, K.,
Gartland, M.,
Karayiannis, P.,
McGarvey, M. J.,
and Clarke, B.
(1999)
J. Gen. Virol.
80,
2337-2341[Abstract/Free Full Text]
|
| 6.
|
Rijnbrand, R.,
Abell, G.,
and Lemon, S. M.
(2000)
J. Virol.
74,
773-783[Abstract/Free Full Text]
|
| 7.
|
Honda, M.,
Brown, E. A.,
and Lemon, S. M.
(1996)
RNA (N. Y.)
2,
955-968[Abstract]
|
| 8.
|
Honda, M.,
Beard, M. R.,
Ping, L. H.,
and Lemon, S. M.
(1999)
J. Virol.
73,
1165-1174[Abstract/Free Full Text]
|
| 9.
|
Wang, C.,
Sarnow, P.,
and Siddiqui, A.
(1994)
J. Virol.
68,
7301-7307[Abstract/Free Full Text]
|
| 10.
|
Wang, C.,
Le, S. Y.,
Ali, N.,
and Siddiqui, A.
(1995)
RNA (N. Y.)
1,
526-537[Abstract]
|
| 11.
|
Kieft, J. S.,
Zhou, K.,
Jubin, R.,
Murray, M. G.,
Lau, J. Y.,
and Doudna, J. A.
(1999)
J. Mol. Biol.
292,
513-529[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Lukavsky, P. J.,
Otto, G. A.,
Lancaster, A. M.,
Sarnow, P.,
and Puglisi, J. D.
(2000)
Nat. Struct. Biol.
7,
1105-1110[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Spahn, C. M.,
Kieft, J. S.,
Grassucci, R. A.,
Penczek, P. A.,
Zhou, K.,
Doudna, J. A.,
and Frank, J.
(2001)
Science
291,
1959-1962[Abstract/Free Full Text]
|
| 14.
|
Kieft, J. S.,
Zhou, K.,
Jubin, R.,
and Doudna, J. A.
(2001)
RNA (N. Y.)
7,
194-206[Abstract]
|
| 15.
|
Kolupaeva, V. G.,
Pestova, T. V.,
and Hellen, C. U.
(2000)
J. Virol.
74,
6242-6250[Abstract/Free Full Text]
|
| 16.
|
Klinck, R.,
Westhof, E.,
Walker, S.,
Afshar, M.,
Collier, A.,
and Aboul-Ela, F.
(2000)
RNA (N. Y.)
6,
1423-1431[Abstract]
|
| 17.
|
Jubin, R.,
Vantuno, N. E.,
Kieft, J. S.,
Murray, M. G.,
Doudna, J. A.,
Lau, J. Y.,
and Baroudy, B. M.
(2000)
J. Virol.
74,
10430-10437[Abstract/Free Full Text]
|
| 18.
|
Rijnbrand, R.,
Bredenbeek, P.,
van der Straaten, T.,
Whetter, L.,
Inchauspe, G.,
Lemon, S.,
and Spaan, W.
(1995)
FEBS Lett.
365,
115-119[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Buratti, E.,
Gerotto, M.,
Pontisso, P.,
Alberti, A.,
Tisminetzky, S. G.,
and Baralle, F. E.
(1997)
FEBS Lett.
411,
275-280[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Buratti, E.,
Tisminetzky, S.,
Zotti, M.,
and Baralle, F. E.
(1998)
Nucleic Acids Res.
26,
3179-3187[Abstract/Free Full Text]
|
| 21.
|
Odreman-Macchioli, F. E.,
Tisminetzky, S. G.,
Zotti, M.,
Baralle, F. E.,
and Buratti, E.
(2000)
Nucleic Acids Res.
28,
875-885[Abstract/Free Full Text]
|
| 22.
|
Fukushi, S.,
Kurihara, C.,
Ishiyama, N.,
Hoshino, F. B.,
Oya, A.,
and Katayama, K.
(1997)
J. Virol.
71,
1662-1666[Abstract]
|
| 23.
|
Tang, S.,
Collier, A. J.,
and Elliott, R. M.
(1999)
J. Virol.
73,
2359-2364[Abstract/Free Full Text]
|
| 24.
|
Hwang, L. H.,
Hsieh, C. L.,
Yen, A.,
Chung, Y. L.,
and Chen, D. S.
(1998)
Biochem. Biophys. Res. Commun.
252,
455-460[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Varaklioti, A.,
Georgopoulou, U.,
Kakkanas, A.,
Psaridi, L.,
Serwe, M.,
Caselmann, W. H.,
and Mavromara, P.
(1998)
Biochem. Biophys. Res. Commun.
253,
678-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Hellen, C. U.,
and Pestova, T. V.
(1999)
J. Viral Hepat.
6,
79-87[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Psaridi, L.,
Georgopoulou, U.,
Varaklioti, A.,
and Mavromara, P.
(1999)
FEBS Lett.
453,
49-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Rijnbrand, R. C.,
Abbink, T. E.,
Haasnoot, P. C.,
Spaan, W. J.,
and Bredenbeek, P. J.
(1996)
Virology
226,
47-56[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Reynolds, J. E.,
Kaminski, A.,
Kettinen, H. J.,
Grace, K.,
Clarke, B. E.,
Carroll, A. R.,
Rowlands, D. J.,
and Jackson, R. J.
(1995)
EMBO J.
14,
6010-6020[Medline]
[Order article via Infotrieve]
|
| 30.
|
Reynolds, J. E.,
Kaminski, A.,
Carroll, A. R.,
Clarke, B. E.,
Rowlands, D. J.,
and Jackson, R. J.
(1996)
RNA (N. Y.)
2,
867-878[Abstract]
|
| 31.
|
Pestova, T. V.,
Shatsky, I. N.,
Fletcher, S. P.,
Jackson, R. J.,
and Hellen, C. U.
(1998)
Genes Dev.
12,
67-83[Abstract/Free Full Text]
|
| 32.
|
Sizova, D. V.,
Kolupaeva, V. G.,
Pestova, T. V.,
Shatsky, I. N.,
and Hellen, C. U.
(1998)
J. Virol.
72,
4775-4782[Abstract/Free Full Text]
|
| 33.
|
Ali, N.,
Pruijn, G. J.,
Kenan, D. J.,
Keene, J. D.,
and Siddiqui, A.
(2000)
J. Biol. Chem.
275,
27531-27540[Abstract/Free Full Text]
|
| 34.
|
Ali, N.,
and Siddiqui, A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2249-2254[Abstract/Free Full Text]
|
| 35.
|
Isoyama, T.,
Kamoshita, N.,
Yasui, K.,
Iwai, A.,
Shiroki, K.,
Toyoda, H.,
Yamada, A.,
Takasaki, Y.,
and Nomoto, A.
(1999)
J. Gen. Virol.
80,
2319-2327[Abstract/Free Full Text]
|
| 36.
|
Hahm, B.,
Kim, Y. K.,
Kim, J. H.,
Kim, T. Y.,
and Jang, S. K.
(1998)
J. Virol.
72,
8782-8788[Abstract/Free Full Text]
|
| 37.
|
Fukushi, S.,
Okada, M.,
Kageyama, T.,
Hoshino, F. B.,
Nagai, K.,
and Katayama, K.
(2001)
Virus Res.
73,
67-79[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Spangberg, K.,
and Schwartz, S.
(1999)
J. Gen. Virol.
80,
1371-1376[Abstract]
|
| 39.
|
Ali, N.,
and Siddiqui, A.
(1995)
J. Virol.
69,
6367-6375[Abstract]
|
| 40.
|
Anwar, A.,
Ali, N.,
Tanveer, R.,
and Siddiqui, A.
(2000)
J. Biol. Chem.
275,
34231-34235[Abstract/Free Full Text]
|
| 41.
|
Kaminski, A.,
Hunt, S. L.,
Patton, J. G.,
and Jackson, R. J.
(1995)
RNA (N. Y.)
1,
924-938[Abstract]
|
| 42.
|
Honda, M.,
Kaneko, S.,
Matsushita, E.,
Kobayashi, K.,
Abell, G. A.,
and Lemon, S. M.
(2000)
Gastroenterology
118,
152-162[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Laporte, J.,
Malet, I.,
Andrieu, T.,
Thibault, V.,
Toulme, J. J.,
Wychowski, C.,
Pawlotsky, J. M.,
Huraux, J. M.,
Agut, H.,
and Cahour, A.
(2000)
J. Virol.
74,
10827-10833[Abstract/Free Full Text]
|
| 44.
|
Brown, E. A.,
Zhang, H.,
Ping, L. H.,
and Lemon, S. M.
(1992)
Nucleic Acids Res.
20,
5041-5045[Abstract/Free Full Text]
|
| 45.
|
Fukushi, S.,
Okada, M.,
Kageyama, T.,
Hoshino, F. B.,
and Katayama, K.
(1999)
Virus Genes
19,
153-161[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Fukushi, S.,
Okada, M.,
Stahl, J.,
Kageyama, T.,
Hoshino, F. B.,
and Katayama, K.
(2001)
J. Biol. Chem.
276,
20824-20826[Abstract/Free Full Text]
|
| 47.
|
Buratti, E.,
Baralle, F. E.,
and Tisminetzky, S. G.
(1998)
Cell. Mol. Biol. (Noisy-le-grand)
44,
505-512[Medline]
[Order article via Infotrieve]
|
| 48.
|
Buratti, E.,
Di Michele, M.,
Song, P.,
Monti-Bragadin, C.,
Scodeller, E. A.,
Baralle, F. E.,
and Tisminetzky, S. G.
(1997)
Clin. Diagn. Lab. Immunol.
4,
117-121[Abstract]
|
| 49.
|
Zhao, W. D.,
and Wimmer, E.
(2001)
J. Virol.
75,
3719-3730[Abstract/Free Full Text]
|
| 50.
|
Di Bisceglie, A. M.
(1999)
Am. J. Med.
107,
45S-48S[Medline]
[Order article via Infotrieve]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. I. Barria, A. Gonzalez, J. Vera-Otarola, U. Leon, V. Vollrath, D. Marsac, O. Monasterio, T. Perez-Acle, A. Soza, and M. Lopez-Lastra
Analysis of natural variants of the hepatitis C virus internal ribosome entry site reveals that primary sequence plays a key role in cap-independent translation
Nucleic Acids Res.,
February 1, 2009;
37(3):
957 - 971.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Pfingsten and J. S. Kieft
RNA structure-based ribosome recruitment: Lessons from the Dicistroviridae intergenic region IRESes
RNA,
July 1, 2008;
14(7):
1255 - 1263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Baird, S. M. Lewis, M. Turcotte, and M. Holcik
A search for structurally similar cellular internal ribosome entry sites
Nucleic Acids Res.,
July 9, 2007;
35(14):
4664 - 4677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Baird, M. Turcotte, R. G. Korneluk, and M. Holcik
Searching for IRES
RNA,
October 1, 2006;
12(10):
1755 - 1785.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Beguiristain, H. D. Robertson, and J. Gomez
RNase III cleavage demonstrates a long range RNA: RNA duplex element flanking the hepatitis C virus internal ribosome entry site
Nucleic Acids Res.,
September 16, 2005;
33(16):
5250 - 5261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Bergeron and J.-P. Perreault
Target-dependent on/off switch increases ribozyme fidelity
Nucleic Acids Res.,
February 24, 2005;
33(4):
1240 - 1248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Ray and S. Das
Inhibition of hepatitis C virus IRES-mediated translation by small RNAs analogous to stem-loop structures of the 5'-untranslated region
Nucleic Acids Res.,
March 12, 2004;
32(5):
1678 - 1687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. VYAS, A. ELIA, and M. J. CLEMENS
Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA
RNA,
July 1, 2003;
9(7):
858 - 870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kikuchi, T. Umehara, K. Fukuda, J. Hwang, A. Kuno, T. Hasegawa, and S. Nishikawa
RNA Aptamers Targeted to Domain II of Hepatitis C Virus IRES That Bind to Its Apical Loop Region
J. Biochem.,
March 1, 2003;
133(3):
263 - 270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Dumas, C. Staedel, M. Colombat, S. Reigadas, S. Chabas, T. Astier-Gin, A. Cahour, S. Litvak, and M. Ventura
A promoter activity is present in the DNA sequence corresponding to the hepatitis C virus 5' UTR
Nucleic Acids Res.,
February 15, 2003;
31(4):
1275 - 1281.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|